Beckman Coulter, a clinical diagnostics leader, unveiled the DxI 9000 Access Immunoassay Analyzer, the most productive immunoassay analyzer per footprint.
Numab Therapeutics AG announced that the first subject has been dosed in the Phase 1 clinical study of NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis.
Rona Therapeutics, Inc and Keymed Biosciences, announced a collaboration to jointly discover and develop first-in-class siRNA therapeutics for Glomerulonephritis.
Innovent Biologics, Inc. announced that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Breakthrough Therapy Designation for IBI351 for the treatment of previously treated advanced colorectal carcinoma patients with KRASG12C mutation.
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 for patients diagnosed with a microorganism infection.
Athenex, Inc. announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company’s assets across its primary businesses: Athenex Pharmaceutical Division, Orascovery, and Cell Therapy.
Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process Read More »
Catalent, Inc. announced it will be postponing the release of its financial results for the third quarter of fiscal year 2023, ended March 31, 2023, and the conference call previously scheduled for Monday, May 15, 2023 at 8:15 a.m.
Catalent Announces Postponement of Third Quarter 2023 Results and Conference Call Read More »
The FDA has four events lined up this week, including a target action date for Krystal Biotech’s gene therapy for a rare skin disease and an adcomm meeting for Pfizer’s RSV vaccine candidate.
FDA Action Alert: Krystal, Genmab/AbbVie, Pfizer and Intercept Read More »
The approval of Reata Pharmaceuticals’ Skyclarys for Friedreich’s ataxia highlights progress being made in the treatment of rare mitochondrial diseases.
Therapies for Rare Mitochondrial Diseases Begin to See Traction Read More »
Developers of psychedelics-based therapies say the industry is poised to explode, with several reporting strong clinical trial results and the FDA granting breakthrough status for two hallucinogenic drugs.
Companies Bank on Psychedelics as Treatments for Mental Health Disorders Read More »
